YOLFTbeta
Argent Biopharma Ltd

Argent Biopharma Ltd

RGT · AU · Healthcare / Drug Manufacturers - Specialty & Generic

0.021AUD+0.00 (+10.53%)

Price History

Full chart

Market Stats

Previous Close0.019
Open0.021
Day Range0.021 – 0.022
52-Week Range0.028 – 0.10
Volume52.50K
Market Cap3.50M
P/E (TTM)0.00
Forward P/E14.37
EPS-0.09
Dividend Yield0.00%
Beta0.40
50-Day Avg0.0358
200-Day Avg0.0446

About

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Roby Reuven Zomer
  • Employees0
  • Headquarters295 Rokeby Road, Subiaco, WA, Australia, 6008, Australia
  • Websitehttps://argentbiopharma.com

Leadership

  • Mr. Roby Reuven ZomerCo-Founder, MD, CEO & Chairman · b. 1980
  • Mr. Andrew Chapman B.Bus(Econ), DFP, GradDipAppFinNon Executive Director · b. 1975
  • Mr. Shachar ShimonyGroup General Counsel
  • Mr. Amir PolakChief Pharmaceutical Development Officer
  • Dr. Nadya LisovoderChief Medical Officer
  • Ms. Sasha FriedmanHead of Information Systems
  • Yair TalChief Information Security Officer
  • Sanja CacovichHead of Non-Pharmaceutical Operations
  • Mr. Rowan Michael HarlandCompany Secretary

Financials

Income Statement

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-04-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue1.81M2.59M1.91M2.22M2.14M36.00K50.00K53.00K25.66K11.00K5.89K2.20K120.24K296.81K656.24K2.08M3.00M4.73M3.39M891.08K583.45K161.19K
Growth (%)-+42.77%-26.34%+16.26%-3.55%-98.32%+38.89%+6.00%-51.58%-57.13%-46.45%-62.70%+5373.01%+146.84%+121.10%+216.83%+44.10%+57.94%-28.41%-73.70%-34.52%-72.37%
Cost of Revenue1.09M2.66M2.76M3.29M3.21M111.55K47.00K70.00K191.73K94.55K0210.05K1.01M1.26M616.39K2.39M2.26M2.92M1.94M687.39K137.12K365.39K
Gross Profit723.24K-73.47K-851.29K-1.07M-1.08M-111.55K--69.91K-191.73K11.36K0-207.86K-888.80K-963.34K39.85K-306.46K736.49K1.81M1.45M203.70K446.32K-204.21K
Gross Margin39.91%-2.84%-44.67%-48.43%-50.33%-309.85%--131.91%-747.19%103.25%0.00%-9460.90%-739.17%-324.56%6.07%-14.74%24.58%38.25%42.82%22.86%76.50%-126.69%
Operating Expense392.47K234.76K799.57K349.40K841.21K140.91K-274.03K573.48K5.36M3.80M2.25M5.85M7.40M9.08M11.50M11.02M16.07M17.05M18.47M15.89M7.19M
Operating Income330.76K-308.23K-1.65M-1.42M-1.92M-252.45K--343.94K-765.21K-5.35M-3.80M-2.46M-6.74M-8.36M-9.04M-11.80M-10.28M-14.26M-15.60M-18.26M-15.44M-7.39M
Operating Margin18.25%-11.91%-86.63%-64.20%-89.69%-701.26%--648.95%-2982.09%-48604.72%-64467.96%-112014.52%-5607.09%-2816.44%-1377.42%-567.76%-343.19%-301.38%-460.46%-2049.40%-2646.84%-4586.90%
EBITDA493.09K-226.81K-1.58M-1.39M-1.82M-354.30K--343.94K-758.56K-500.20K-853.49K-6.09M-8.40M-10.46M-11.09M-18.58M-15.39M-16.70M-20.04M-15.77M-17.00M-7.23M
EBITDA Margin27.21%-8.77%-82.66%-62.60%-85.36%-984.17%--648.95%-2956.21%-4547.27%-14490.48%-277354.48%-6984.90%-3525.76%-1690.54%-893.75%-513.83%-352.94%-591.65%-1770.00%-2914.38%-4484.80%
Net Income252.71K-284.40K-1.89M-1.95M-3.18M-617.21K--290.88K-766.90K-5.34M-3.80M-6.16M-8.14M-8.25M-8.58M-19.36M-15.87M-16.77M-20.82M-17.53M-17.84M-7.71M
Net Income Margin13.95%-10.99%-98.97%-87.82%-148.81%-1714.46%--548.83%-2988.69%-48525.59%-64478.62%-280252.34%-6773.31%-2778.31%-1307.35%-931.29%-529.70%-354.31%-614.71%-1967.34%-3058.43%-4783.36%
R&D----------951.32K951.32K951.32K951.32K3.70M5.37M3.60M2.72M1.99M2.32M3.59M490.19K
R&D as % of Total Revenue----------16151.49%43301.00%791.17%320.51%564.35%258.28%120.04%57.43%58.82%260.51%615.57%304.11%
Interest Expense95.86K25.89K11.34K523.18K1.32M95.14K00000120.01K19.72K99.37K444135.58K369.13K190.05K337.01K482.47K51.30K33.71K
Interest Expense % of Total Revenue5.29%1.00%0.60%23.61%61.72%264.27%0.00%0.00%0.00%0.00%0.00%5462.27%16.40%33.48%0.07%6.52%12.32%4.02%9.95%54.14%8.79%20.91%

Balance Sheet

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-04-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets5.37M4.54M2.64M16.42M14.13M1.09M752.00K992.36K8.70M4.98M2.52M16.36M20.82M19.99M13.00M7.93M24.24M18.56M9.98M10.79M2.47M1.29M
Total Liabilities2.61M725.36K703.90K16.43M17.27M265.52K312.00K204.94K758.99K429.29K593.79K4.63M5.03M7.30M2.20M4.83M10.41M13.38M18.02M16.61M11.10M10.74M
Total Equity2.76M3.81M1.94M-8.80K-2.59M828.30K440.00K787.42K7.94M4.55M1.93M11.81M16.23M13.93M10.96M3.11M13.83M5.84M-7.40M-5.15M-8.63M-9.45M
Cash2.76M1.14M636.47K889.61K59.47K1.07M713.00K515.83K161.43K595.09K436.99K7.90M11.36M9.86M2.35M1.87M5.43M1.89M239.82K702.87K1.02M141.46K
Total Debt2.48M144.47K90.41K10.20M14.96M37.83K--406.40K195.00K195.00K1.10M40.62K43.12K1.90M1.90M6.02M4.52M9.75M1.04M8.29M9.59M
Net Debt2.48M144.47K90.41K10.20M14.90M-1.03M--515.83K244.97K-595.09K-241.99K-6.80M-11.34M-9.84M-2.35M25.85K584.33K2.47M9.51M341.85K7.26M9.45M

Cash Flow

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-350.83K-1.63M-460.26K-416.04K-1.04M-338.82K-379.45K-536.08K-472.74K-617.71K-3.22M-4.66M-5.89M-6.35M-9.96M-11.99M-12.16M-11.99M-14.66M-9.28M-4.03M
Investing Cash Flow-156.16K-76.99K---14.88K-5.00K--2.22M-507.88K-316.40K-650.94K-631.23K-340.58K-947.03K-969.88K-1.49M-1.11M606.20K-140.12K208.83K-721
Financing Cash Flow110.47K2.73M187.91K11.30M227.28K1.40M-175.61K2.43M1.42M776.56K11.33M8.81M4.70M27.01K10.46M17.05M9.74M9.73M15.27M9.39M3.14M
Capital Expenditure156.17K56.26K37.89K124.47K5.68K408.33K507.88K388.52K1.13M459.44K377.04K962.09K3.33M2.69M189.88K140.12K2.23K1.61K
Free Cash Flow-507.00K-1.68M-498.15K-540.51K-1.05M-338.82K-379.45K-544.41K-472.74K-617.71K-3.31M-5.79M-6.35M-6.73M-10.92M-15.32M-14.85M-12.18M-14.80M-9.28M-4.03M
Dividends Paid79.87K---------00--9.67M16.10M9.24M9.62M---
FCF to OCF144.51%103.46%108.23%129.92%100.54%100.00%100.00%101.55%100.00%100.00%102.75%124.30%107.80%105.93%109.66%127.75%122.12%101.58%100.96%100.02%100.04%
Dividend Paid to FCF-15.75%---------0.00%0.00%---88.60%-105.14%-62.21%-78.98%---

Earnings

Report DateFeb 3, 2016Aug 29, 2016Feb 28, 2017Aug 30, 2017Feb 26, 2018Sep 2, 2018Feb 28, 2019Aug 28, 2019Feb 28, 2020Aug 31, 2020Feb 26, 2021Aug 30, 2021Dec 1, 2021Feb 27, 2022Jun 1, 2022Sep 1, 2022Nov 30, 2022Feb 28, 2023Apr 28, 2023Sep 29, 2023Oct 30, 2023Feb 28, 2024May 29, 2024Aug 30, 2024Nov 27, 2024Feb 28, 2025May 28, 2025Sep 30, 2025Dec 3, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.010.000.00-0.01-0.010.000.000.00-0.010.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.240.00-0.090.00
Surprise-----------------------------
Timing---------------Pre-market-After-hoursPre-marketAfter-hoursAfter-hours--------

Key Statistics & Ratios

Market Cap3.50M
Enterprise Value13.29M
Trailing P/E0.00
Forward P/E14.37
Price / Sales21.70
Price / Book9.85
EPS-0.09
Book Value-0.101
Revenue (TTM)161.19K
Gross Profit (TTM)-39.62K
EBITDA-7.38M
Profit Margin0.00%
Operating Margin43133.83%
Return on Equity-307.40%
Return on Assets-246.78%
Shares Outstanding116.61M
Shares Float40.17M
Beta0.40
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 29, 20231:1000
  • Aug 21, 20121:10